Wylie Vale
Salk Institute for Biological Studies
877 Papers
19.7K Citations
Wylie Vale is an academic researcher from Salk Institute for Biological Studies. The author has contributed to research in topics: Receptor & Somatostatin. The author has an hindex of 163, co-authored 876 publications. Previous affiliations of Wylie Vale include Texas Tech University Health Sciences Center & Hammersmith Hospital.
Chat about Author
Papers
Suppressive actions of a gonadotropin-releasing hormone antagonist on luteinizing hormone, follicle-stimulating hormone, and prolactin release in estrogen-deficient postmenopausal women.
Randall J. Urban,Spyros N. Pavlou,Jean Rivier,Wylie Vale,Maria L. Dufau,Johannes D. Veldhuis +5 more
TL;DR: It is concluded that this gonadotropin-releasing hormone antagonist can achieve effective, potent, and long-lasting suppression of pituitary secretion of biologically active luteinizing hormone at higher doses, but secretion of bioactive luteInizing hormone may "escape" at lower doses.
22
Analogues of luteinizing hormone releasing factor modified at positions 2, 6, and 10.
TL;DR: Biological activities of these analogues of luteinizing hormone releasing factor were determined in vitro, using LRF as the standard for the agonists and [des-His2,D-Ala6]-LRF for the antagonists.
21
Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle.
TL;DR: It is demonstrated that CRFR2 gene transcription in the mature mouse is stimulated by both high-fat diet and chronic variable stress conditions, and the current findings further position the SMCRFR2 pathways as a relevant physiological system that may affect the known reciprocal relationship between psychological and physiological challenges and the metabolic syndrome.
The Local Control of the Pituitary by Activin Signaling and Modulation.
Louise M. Bilezikjian,Wylie Vale +1 more
TL;DR: Special emphasis is given to the TGF-β family of growth factors, in particular activin effects on the gonadotrope population, because a considerable body of evidence supports their contribution to the local modulation of the embryonic and postnatal pituitsary as well as pituitary pathogenesis.
Patent
CRF And analogs
Wylie Vale,Joachim Spiess,Catherine Rivier,Jean Rivier +3 more
- 17 May 1982
TL;DR: A number of analogs have been synthesized that are at least as potent as CRF, and these analogs or pharmaceutically acceptable salts thereof can be administered to mammals to achieve a substantial elevation of ACTH, endorphin, β-lipotropin and corticosterone levels and/or a lowering of blood pressure over an extended period of time as mentioned in this paper.
21